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Purpose. Tumor gene expression after the intravenous (i.v.) administration of current polymer-based
gene delivery systems is generally low and short-lived. Immune stimulatory CpG dinucleotides, present
within the plasmid DNA of the polyplexes are likely to contribute to this. The effect of CpG replacement
on the levels of transgene expression was studied, after the i.v. administration of polyethylenimine (PEI)
polyplexes.
Methods. Tumor transfection and immune stimulation of PEI polyplexes containing plasmid DNA
encoding for luciferase and rich in CpG motifs was monitored and compared to polyplexes containing the
same gene but devoid of CpG motifs. Lipoplexes based on 1,2-dioleyl-3-trimethylammonium-propane/
dioleoylphosphatidylethanolamine liposomes were included as a control.
Results. The replacement of CpGrich DNA by CpGfree DNA did neither affect the physical properties
of the DNA complexes nor did it affect their in vitro transfection activity or cytotoxicity. The immune
stimulation (interleukin-12) after i.v. administration of the PEI DNA complexes was low and unaffected
by the presence of CpG motifs. The absence of CpG motifs within the different DNA complexes
improved the degree and the duration of organ and tumor gene expression.
Conclusion. The depletion of CpG dinucleotides within the plasmid DNA of polyplexes enhances the
degree and duration of in vivo transgene expression.
KEY WORDS: CpG dinucleotides; gene delivery; gene expression; immune stimulation; intravenous;
lipoplexes; plasmid DNA; polyplexes; tumor.
INTRODUCTION
The emerging field of gene therapy offers a number of
exciting potential strategies for treating cancer (1). Cancer
gene therapy aims to achieve the sustained expression of a
variety of anti-tumor proteins (like e.g. tumor-suppressor
proteins, antigens, cytokines and suicide proteins) (2,3).
Systemic application is often to be preferred as it enables to
reach tumor sites which cannot be reached by local injection
(3). The tumor transfection activity of systemically adminis-
tered plasmid DNA can be greatly increased upon complex-
ation with non-viral carrier systems. Complexation of plasmid
DNA with cationic polymers or cationic liposomes leads to
the formation of positively charged nano-sized complexes
(further referred to as polyplexes and lipoplexes, respective-
ly) protecting the complexed DNA against nuclease activity.
In addition, the positively charged DNA polyplexes are
readily taken up by target cells and have demonstrated to
enhance transfection activity of the complexes compared to
uncomplexed DNA (4). Nevertheless, intravenous (i.v.)
administration of non-viral gene delivery systems generally
results in low and transient tumor transgene expression levels
(5–7).
Bacterial CpG dinucleotides have been identified to be
major contributors to the low and short-lived transgene
expression in vertebrates after non-viral gene delivery (8).
CpG dinucleotides are immunostimulatory motifs which are
present within bacterially produced plasmid DNA. Whereas
CpG dinucleotides in bacterial DNA are unmethylated, in
vertebrate DNA they are methylated and occur less frequent
(9). After i.v. administration of the DNA complexes, they are
captured and endocytosed by macrophages and other im-
mune cells. CpG motifs within the plasmid DNA are
recognized as a pathogen-associated molecular pattern upon
acidification of the endosome, by the toll-like receptor 9
(TLR-9) which is present at the endosomal membrane (10).
TLR9-mediated intracellular signaling leads to a pleiotropic
inflammatory response that includes the production of large
amounts of pro-inflammatory cytokines, among which tumor
necrosis factor-alpha, type I interferons, and interleukin 12
(IL-12), and the activation of a variety of immune cells of the
innate and adaptive immune system (e.g. natural killer-cells,
T-cells, macrophages) (9). The increased production of pro-
inflammatory cytokines increases the risk for systemic
toxicity.
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non-viral gene delivery via different mechanisms. The induced
pro-inflammatory cytokines exert a direct inhibitory effect on
transgene transcription by initiating plasmid promoter shut-
down (11). Moreover, high local levels of pro-inflammatory
cytokines can initiate apoptosis of transfected cells. In addition,
activation of immune cells has been reported to eliminate
transfected cells and transgene products (12–14). Finally,
transgene expression of episomal plasmids can be limited by
de novo methylation of the unmethylated bacterial CpG
motifs. Cytosine methylation is a naturally-occurring DNA
modification in vertebrates which interferes with transgene
transcription, resulting in transcriptional silencing (15–17).
Though the immunostimulatory effect of DNA com-
plexes containing unmethylated CpG motifs is being
exploited in cancer immunotherapy (18–20), it should be
minimized in gene therapy strategies where high and long-
lasting transgene levels are desired (12,21). Several strategies
have been studied to limit the immunostimulatory response to
i.v. administrated DNA complexes (22) (1) directing the DNA
complexes to the target cells (23,24), (2) co-administering
macrophage depleting agents, immunosuppressant agents, or
inhibitors of endosomal acidification (25–27), and (3) modi-
fying the plasmid DNA by the in vitro methylation of
unmethylated CpG motifs, by the removal of these motifs,
or by the addition of so-called neutralizing motifs (25,26,28–
30). Whereas all three strategies have shown to result in a
reduced inflammatory toxicity of cationic lipoplexes, CpG
removal appears to outweigh all other strategies when the
effects on transgene expression are considered. Yew et al.( 26,
29) showed that a reduction of the number of unmethylated
CpG motifs within i.v. administered lipoplexes not only
improved the degree but also the duration of transgene
expression in liver and lung up to 49 days post-injection (p.i.).
Similar studies have demonstrated the effects of CpG motif
depletion in naked DNA formulations on transgene expres-
sion (31,32). Recently, Park et al.( 33) demonstrated the
advantage of CpG motif reduction in polymer-based formu-
lations, using minicircle plasmid DNA. The immunogenicity
of minicircle plasmids is strongly reduced by the selective
excision of non-functional or immunostimulatory plasmid
elements. Nevertheless, in these plasmids there is still a
number of CpG motifs present. To our knowledge, no study
addressed the potential benefits of complete CpG depletion
in polymer-based formulations. The aim of the present study
was to evaluate the effect of CpG depletion on the levels of
transgene expression, after i.v. administration of PEI22
polyplexes. PEI22 (Mw 22 kDa) is a linear cationic polymer
and is considered as the gold standard within the field of non-
viral i.v. gene delivery (34). As a control, we included
lipoplexes based on cationic liposomes composed of 1,2-
dioleyl-3-trimethylammonium-propane/dioleoylphoshatidyl-
ethanolamine (DOTAP/DOPE), a lipoplex formulation
which is frequently used in i.v. gene delivery (35,36).
MATERIALS AND METHODS
Materials
The plasmid pCpGvitro neomycin–luciferase (neo–luc),
further referred to as pCpGfree, is a 7,114-bp plasmid devoid
of CpG dinucleotides, and was purchased from Cayla SAS
(Toulouse, France). The plasmid contains the coding se-
quence for firefly luciferase and is under transcriptional
control of a composite promoter consisting of a mouse
cytomegalovirus (mCMV) enhancer and the eukaryotic
elongation factor-1 alpha (EF-1α) core promoter. EF-1α is
an enzyme catalyzing the guanosine triphosphate-dependent
binding of tRNA to ribosomes and is abundantly expressed in
almost all kinds of mammalian cells (6). The plasmid has been
synthesized by replacing all CpG dinucleotide containing
codons for codons devoid of CpG dinucleotides,
corresponding to the same amino acid. By these means, a
new codon-optimized gene was created encoding for proteins
whose amino acid sequence remains identical to the wild-type
counterparts. Porcine cytomegalovirus (pCMV)-Luc, a plas-
mid containing the coding sequence for firefly luciferase, was
purchased from Elim Biopharmaceuticals (St. Hayward, US).
The 6,201-bp plasmid is under transcriptional control of the
cytomegalovirus (CMV) immediate promoter and contains
638 CpG motifs. The QuickChange Site-Directed Mutagene-
sis kit and Pfu polymerase were purchased at Stratagene (La
Jolla, US), primers for the site-directed mutagenesis were
ordered at Eurogentec (Seraing, Belgium). The restriction
enzymes PstI, SacI, NcoI, and T4 DNA ligase were purchased
from Fermentas (St. leon-Rot, Germany). PacI was ordered
at Westburg B.V. (Leusden, The Netherlands). The Nucleo-
bond PC 10,000 EF DNA purification (Macherey-Nagel) was
purchased from Bioke (Leiden, The Netherlands). The lipids
DOTAP and DOPE were ordered at Avanti Polar lipids
(Alabaster, USA) and Lipoid (Ludwigshafen, Germany),
respectively. Linear polyethylenimine (PEI22, Mw 22 kDa)
was a generous gift from Prof. Dr. E. Wagner (Ludwig-
Maximilians-Universität, München, Germany). Luciferase
assay reagent, reporter gene lysis buffer, and Quantilum
recombinant luciferase were obtained from Promega (Leiden,
The Netherlands). The Quantikine mouse IL-12 p70 immu-
noassay was purchased from R&D systems (Abingdon Park,
UK).
Methods
Plasmid Construction and Purification
A CpGrich control plasmid, bearing 542 CpG dinucleo-
tides (further referred to as pCpGrich) was constructed by
replacing the promoter/5′-untranslated region (UTR) of the
purchased vector pCMV-Luc with the composite enhancer/
core-promoter and 5′UTR region of pCpGfree. To enable
excision of the original promoter/5′-UTR region, a PstI
restriction site was introduced into pCMV-Luc, by replacing
the TT dinucleotide to CA, at position −8 relative to the
transcription start. A site-directed mutagenesis was per-
formed using the QuickChange Site-Directed Mutagenesis
Kit and two 40 bp primers(5′-CATTAGCATTCCGG
TACTGCAGGTAAAATGGAAGACGCCA-3′ and 5′-
TGGCGTCTTCCATTTTACCTGCAGTACCGGAATGC
TAATG-3′, bold letters refer to added PstI site). The original
promoter/5′-UTR region of the modified pCMV-Luc was
excised by digestion with SacI and PstI (−750 to −6 relative to
the transcription start). The linearized vector, devoid of
promoter, was isolated by preparative gel electrophoresis,
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The insert, consisting of the enhancer/promoter/5′-UTR
region of pCpGfree (position −1,258 to −1, relative to the
transcription start) was excised by digestion of pCpGfree with
PacI and NcoI. The insert was isolated by preparative gel
electrophoresis, blunted with Pfu polymerase and a deoxy-
nucleotide triphosphate mix, and ligated into the blunted
vector, resulting from the excised pCMV-Luc to create
pCpGrich, at a 1:3 vector to insert ratio, using T4 DNA
ligase. E. coli XL-1 Blue supercompetent cells (Stratagene)
were transformed with the resulting plasmid and screened for
the proper insert direction by restriction enzyme digestion.
pCpGfree and pCpGrich were grown in E. coli and
purified to an endotoxin free grade (<0.1 EU/μg DNA), using
a Nucleobond PC 10,000 EF kit.
Preparation of the DNA Complexes
DOTAP/DOPE liposomes were prepared by dissolving
an equimolar amount of DOTAP and DOPE in chloroform
and methanol. The solution was evaporated under reduced
pressure and the lipid film was subsequently hydrated in 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes)
10mM,pH 7.4(totallipid concentration 20mM).Theresulting
liposome dispersion was extruded several times through two
stacked polycarbonate filters (Poretics, Livermore, USA, 200
and 100 nm pore size) with a high-pressure extrusion device
until the desired diameter was obtained (100–120 nm).
DNA complexes were made at different molar ratios of
cationic and anionic charge (N/P ratio), corresponding to the
ratios of nitrogen of the polymer or lipid and the anionic
DNA phosphates. A mass per charge of 43, 698 and 330 Da
was used for PEI22, DOTAP and DNA, respectively. DNA
complexes for in vitro use were prepared at a final DNA
concentration of 10 μg/ml in Hepes (20 mM Hepes, pH 7.4)
or in Hepes-buffered saline (20 mM Hepes, 0.9% g/v NaCl,
pH 7.4). Lipoplexes were prepared by adding one volume of
a DNA solution to one volume of a liposome dispersion,
followed by mixing. Polyplexes were prepared by adding four
volumes of the polymer solution to one volume of DNA
solution and subsequent mixing. DNA complexes for in vivo
studies were prepared at a final DNA concentration of
150 μg/ml in 20 mM Hepes, pH 7.1. Lipoplexes were
prepared at an N/P ratio of 4, as aforementioned. Polyplexes
were prepared at an N/P ratio of 6, by adding one volume of a
polymer solution to one volume of a DNA solution and
subsequent mixing. After preparation, one tenth a volume of
a 50% g/v D-glucose in 20 mM Hepes, pH 7.1 stock was
added to obtain an isotonic dispersion (37). All complexes
were incubated for 30 min at room temperature, prior to use.
Complex Characterization
The average hydrodynamic diameter and the zeta
potential of the DNA complexes was determined using
dynamic light scattering (ALV CGS-3 system, Malvern
Instruments, UK) and electrophoretic mobility (Zetasizer
Nano-Z, Malvern instruments) measurements, in 20 mM
Hepes pH 7.4, at a DNA concentration of 10 μg/ml. Both
instruments were calibrated using polystyrene latex beads of
defined size and zeta-potential.
Complex cytotoxicity and in vitro transfection activity
Neuro 2A cells (Murine Neuroblastoma, ATCC CCL-
131) were cultured in RPMI 1640 medium completed with
bovine calf serum (10%) and antibiotics/antimycotics (100 U/
ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphoter-
icin B) at 37°C at a 5% CO2 humidified atmosphere.
Transfection activity and cytotoxicity of the complexes
was determined 24 and 72 h after incubation of the complexes
with the cells (1 h), in serum containing medium, as described
earlier (38). Experiments were carried out twice in triplicate
in two separate 96-well plates. One series was tested for
luciferase expression (38), the other series was tested for cell
viability using an XTT based colorimetric assay (38,39).
Luciferase activity of the cells was determined after cell lysis
using a Fluostar Optima Fluorimeter equipped with a
luminescence light guide (BMG LabTech, Germany). Trans-
fection activity of the complexes was expressed as relative
light units (RLU), corrected per microgram total protein
(Micro BCA Protein Assay, Pierce, The Netherlands).
Cytotoxicity of the complexes was determined by assessing
the percentage of viable cells after transfection, normalized to
values obtained after incubation with buffer only (38).
In Vivo Studies
The animal experiments were performed according to
national regulations and approved by the local animal
experiments ethical committee. Six-week old male A/J mice
(Harlan, The Netherlands) were inoculated with 1×10
6 Neuro
2A cells in the left flank. Seven to 12 days after inoculation, at
an average tumor volume of 0.4–0.9 cm
3, the different
formulations were injected into the tail vein of the mice
(0.2 ml, corresponding with 30 μg DNA).
At 3, 5 and 7 h post-injection, blood was collected by
saphenous venepuncture. Blood samples were allowed to
coagulate at 4°C for 4 h and then centrifuged at 4,000×g for
10 min. Serum was collected, diluted with phosphate-buffered
saline and kept at −80°C until analysis. IL-12 serum levels
were determined using a Quantikine mIL-12 immunoassay.
One, 5 or 11 days post-injection, mice were sacrificed by
cervical dislocation and luciferase levels of the tumor and the
different organs was assessed as previously described (40).
Luciferase levels were expressed as relative light units per
organ (or per gram tumor). In this setting, 6×10
3 RLU
corresponds to 1 pg of recombinant luciferase.
Statistical Analysis
Statistical analysis was performed using GraphPad InStat
3.06. A p-value of < 0.05 was considered to be significant
(two-tailed). The Grubb’s test for detecting outliers was used
for identifying outliers.
RESULTS AND DISCUSSION
Plasmid DNA Characteristics
pCpGvitro neo-luc (further referred to as pCpGfree) is a
commercially available 7,114-bp plasmid devoid of CpG
dinucleotides. It contains the coding sequence for firefly
1656 de Wolf et al.luciferase and is under transcriptional control of a composite
promoter consisting of a mCMV enhancer and the EF-1α
core promoter (Fig. 1).
A control vector, a 6,724 bp plasmid bearing 542 CpG
motifs (further referred to as pCpGrich) was constructed by
replacing the promoter/5′-UTR region of a purchased vector
pCMV-Luc with the composite core-promoter/enhancer and
5′UTR region of pCpGfree.
Characterization of the DNA Complexes
pCpGfree and pCpGrich were complexed with PEI22
(Mw 22 kDa) and the cationic liposome formulation DOTAP/
DOPE. PEI22 has proven to be one of the most efficient
cationic polymers for in vitro and in vivo gene transfer (41).
DOTAP is a cationic lipid, commonly used for liposome-
mediated transfection (36). Co-inclusion of the helper lipid
DOPE improves the lipoplex transfection activity by facili-
tating endosomal membrane destabilization (42).
The physical characteristics of the PEI22- and DOTAP-
complexes prepared with pCpGrich or pCpGfree were
determined. Under the experimental conditions, size and zeta
potential of the complexes was not affected by the type of
plasmid used (Tables I and II, p≥0.08). Positively charged
polyplexes were formed after condensation with PEI22 at a
DNA concentration of 10 μg/ml (zeta potential approximately
+25–+31 mV, Table I). Polyplexes were smallest at an N/P
ratio of 6 and 9. Complexation of DNA with DOTAP
liposomes at an N/P ratio of 2 resulted in lipoplexes bearing
a strong negative zeta potential. Likely, at this lipid to DNA
ratio, the amount of cationic lipid is inefficient to complex all
DNA present. Lipoplexes prepared at an N/P of 4 and
8 demonstrated a strongly positive zeta potential (+48–
+57 mV). The mean size of the lipoplexes was relatively
large (320–610 nm) when compared to that of the polyplexes
(120–170 nm). Complexes were stable over a period of
several days at room temperature.
Complex Cytotoxicity and In Vitro Transfection Activity
The effect of plasmid replacement (pCpGrich to
pCpGfree) on the cytotoxicity (Fig. 2) and in vitro transfec-
tion activity (Fig. 3) of PEI22 and DOTAP complexes was
studied, using Neuro 2A cells. Relative cell viability after
incubation with the different DNA complexes was not
affected by the type of plasmid used. PEI22 complexes
showed considerable cytotoxicity (Fig. 2A). A 50% reduction
in cell viability was observed at an N/P ratio of 6, 24 h after
transfection. Incubation of the cells with the DOTAP com-
plexes did not affect cell viability, at any of the N/P ratios
investigated (Fig. 2B). Similar results were observed at 72 h
after incubation (data not shown).
Replacement of pCpGrich by pCpGfree within both
DNA complexes did not influence their respective in vitro
transfection activities (Fig. 3). Highest levels of luciferase
transgene expression were mediated by PEI22 polyplexes,
prepared at an N/P ratio >6 (Fig. 3A). Transfection activity of
DOTAP lipoplexes was highest at an N/P ratio of 2–4
(Fig. 3B), being tenfold lower than observed for the PEI22
polyplexes. The high ionic strength of the transfection
medium favors the formation of aggregates at these specific
N/P ratios (data not shown). Aggregate formation of the
DNA complexes has likely contributed to the enhanced
transfection activity as it promotes cellular contact and
internalization (43). The similar short-term gene expression
profiles observed for the two different plasmid types was
expected as they bear the same transcription initiation sites.
Apparently, the extensive sequence differences within the
plasmid regions upstream of the EF1α 5′-UTR did not
substantially affect the initial transcription rate of the
plasmids.
In Vivo Inflammatory Response
The immunostimulatory activity of the different CpGfree
and CpGrich formulations were tested by determining serum
IL-12 levels after i.v. injection (30 μg DNA). As a result of
the high inter individual differences in onset and level of
inflammatory response, the IL-12 levels measured were
Table I. Mean Particle Size (nm) and Zeta Potential (mV) of pCpGrich and pCpGfree Complexes at a DNA Concentration of 10 μg/ml
Formulation pCpGrich pCpGfree
N/P ratio Size Zeta potential Size Zeta potential
PEI22 3 590 (±210) 31 (±7.4) 990 (±1,000) 25 (±15)
6 170 (±20) 27 (±0.4) 170 (±10) 27 (±0.5)
9 120 (±0) 25 (±1.2) 130 (±10) 25 (±0.2)
DOTAP 2 320 (±20) −58 (±1.6) 320 (±10) −59 (±0.9)
4 540 (±10) 51 (±0.8) 610 (±90) 48 (±3.3)
8 430 (±10) 55 (±1.4) 460 (±20) 57 (±0.5)
Mean (±SD), n=3. Polydispersity values of the complexes were within acceptable limits (<0.30), indicating rather monodisperse formulations.
0                 1                 2                 3 Size (kbp)  4                 5                 6                 7 
CMVenh.    EF1α                                                 
EF1αprom.   5’-UTR           LUC                       pAn          SV40enh.prom.Neo        Rk6Ori           pCpGfree 
   7.1 kbp 
pCpGrich 
6.7 kbp 
CMVenh.    EF1α                                                  
EF1αprom.   5’-UTR           LUC                        pAn         CMVprom.Amp             ColE1Ori       
Fig. 1. Linearized diagram of pCpGfree and pCpGrich. CMVenh.
EF1prom .: composite promoter based on cytomegalovirus enhancer
and mouse elongation factor-1 alpha core promoter. EF1 5′-UTR,5 ′
untranslated region of mouse elongation factor-1 alpha; LUC, exon
encoding for firefly luciferase; pAn, polyadenylation signal; Neo,
neomycin resistance; Amp, ampicillin resistance; Ori,o r i g i no f
replication. One arrow represents approximately 20 unmethylated
CpG dinucleotides.
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PEI22 induced low serum IL-12 levels (Fig. 4A). Replace-
ment of pCpGrich by pCpGfree did not affect the IL-12
serum levels observed after administration. IL-12 levels after
administration of the CpGrich cationic liposome formulation
were higher than the levels observed for the PEI22 poly-
plexes (Fig. 4B; p<0.05). These findings are in line with
earlier reports (44,45). CpG depletion significantly decreased
the serum IL-12 levels at 3 and 7 h after administration of the
liposome formulation, which is again in line with earlier
reports (8,26,29,44).
After i.v. administration, lipoplexes and polyplexes
accumulate to a high extent in the liver as a result of their
efficient uptake by Kupffer cells (46). Previous reports
suggest that the systemic cytokines produced after i.v.
administered lipoplexes can be attributed to uptake and
intracellular processing of the lipoplexes by Kupffer cells
(24,47). It is unlikely that the observed differences in immune
stimulation by PEI22 and DOTAP complexes originate from
major differences in tissue accumulation, with PEI22 poly-
plexes showing less uptake by Kupffer cells (45). We
speculate that differences in the pathway of cellular uptake
of the DNA complexes by the immune cells may have
contributed to the observed differences in the induced
inflammatory response. Whereas lipoplexes are endocytosed
exclusively via clathrin-dependent pathways, polyplexes are
taken up by clathrin- as well as caveolae-dependent pathways
(48,49). It may be that the caveolae-dependent pathway does
Fig. 2. Relative cell viability of Neuro 2A cells, 24 h after incubation
with PEI22 (A) and DOTAP (B) based DNA complexes. DNA
complexes contained CpGrich (filled square) or CpGfree (filled
triangle) DNA. Experiments were carried out twice in triplicate.
Values are normalized against buffer treated cells (mean+SD, n=3).
Table II. Mean Particle Size (nm) of pCpGrich and pCpGfree Complexes at a DNA Concentration of 150 μg/ml
Formulation N/P ratio pCpGrich pCpGfree
PEI22 6 170 (±40) 160 (±60)
DOTAP 4 280 (±20) 310 (±40)
Mean (±SD), n=3, Polydispersity values of the complexes were within acceptable limits (<0.30), indicating rather monodisperse formulations.
Fig. 3. In vitro gene expression in Neuro 2A cells, 24 h after
transfection with PEI22 (A) and DOTAP (B) based DNA complexes.
DNA complexes contained CpGrich (filled square) or CpGfree (filled
triangle) DNA. Experiments were carried out twice in triplicate.
Values are corrected per microgram protein (mean+SD, n=3).
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cellular activation.
In Vivo Gene Expression
The effect of plasmid replacement on tumor luciferase
expression was determined, at different time-points after i.v.
injection of PEI22 or DOTAP complexes in mice, bearing a
subcutaneous (s.c.) Neuro 2A tumor (30 μg DNA, Fig. 5).
Significant gene expression was detected in the tumor, 1 day
after administration of pCpGrich complexed with PEI22
(Fig. 5A). The replacement of pCpGrich by pCpGfree
enhanced the degree of gene expression approximately four-
fold (p<0.05). Moreover, CpG depletion improved the
duration of tumor transgene expression. Five days after
administration, luciferase levels had dropped 50-fold in the
case of pCpGrich-based transfection, whereas luciferase
levels were similar to day 1 p.i. in case of pCpGfree-based
transfection (p<0.05). Eleven days after injection, luciferase
levels of both plasmid types had decreased to background
levels. Similar effects were observed in case of tumor
luciferase expression mediated by DOTAP lipoplexes
(Fig. 5B). CpG depletion of DOTAP lipoplexes enhanced
the degree of tumor luciferase expression 20-fold, at day 1 p.i.
Again, transgene expression endured to at least 5 days, using
the CpGfree complexes (p<0.05).
The distribution of luciferase expression in the major
organs was assessed after i.v. administration of both CpGrich
and CpGfree complexes. Transgene expression was highest in
the lungs, the liver and the spleen (Fig. 6A–F). Transgene
expression in kidney and heart is not shown.
Injection of CpGrich PEI22 complexes mediated highest
transgene expression in the lungs (Fig. 6A). CpG depletion
did not significantly affect the degree of luciferase expression
at day 1, 5 and 11 p.i., although mean levels were higher. In
the case of DOTAP-mediated transfection, lung expression
was low and only detectable at day 1 and 11 after
administration of CpGfree complexes (Fig. 6B, p<0.05).
Various factors may explain the significant difference in gene
expression of polyplexes and lipoplexes, at the different time-
points. Aggregation has been reported to be a dominant
factor in lung uptake (50–52). Both systems may have
differed in the degree of aggregation upon introduction into
the bloodstream. A second explanation relates to earlier
observations demonstrating that alveolar cells were reached
after the intravenous administration of several DNA com-
plexes, as a result of the transient opening of the endothelial
Fig. 4. Box and whisker plot of the serum IL-12 levels of mice after
i.v. administration of PEI22 (A) and DOTAP (B) based DNA
complexes in A/J mice (200 μl, containing 30 μg DNA; n=6).
X symbols represent values which were identified as outliers.
Fig. 5. Tumor gene expression after i.v. administration of PEI22 (A)
and DOTAP (B) based DNA complexes in A/J mice bearing a s.c.
Neuro 2A tumor (200 μl, containing 30 μg DNA; mean+SD, n=3).
Average tumor weight at day 1, 5 and 11 was 0.6, 1.1 and 1.9 g,
respectively.
1659 Plasmid CpG Depletion Improves Degree and Duration of Tumor Gene Expressioncell lining (31,53–55). The DNA complexes investigated in
this study might have differed in their ability to penetrate the
endothelial cell lining.
Liver (Fig. 6C,D) and spleen (Fig. 6E,F) gene expression
were significantly enhanced at all time-points evaluated, upon
replacement of pCpGrich by pCpGfree in the different DNA
complexes (p<0.05). Interestingly, significant luciferase levels
in the latter organs persisted over at least 11 days. The
prolongation of transgene expression is in good agreement
with earlier publications. Yew et al. demonstrated transgene
liver expression persisting over a period of 28–42 days, after
i.v. transfection with lipoplexes with a reduced number of
CpG motifs (26). Also, Park et al. demonstrated increased
transgene adiponectin serum levels over a period of 2–5 days,
Fig. 6. Organ gene expression after i.v. administration of PEI22 (A, C, E) and DOTAP (B, D, F) based DNA complexes in A/J mice bearing a
s.c. Neuro 2A tumor (200 μl, containing 30 μg DNA). Lung (A, B), liver (C, D), spleen (E, F; mean+SD, n=3).
1660 de Wolf et al.after administration of PEI polyplexes consisting of minicircle
DNA, compared to PEI polyplexes bearing the complete
bacterial expression cassette (33).
The beneficial effects of CpG depletion on the duration
of luciferase expression was more pronounced in the liver and
in the spleen, when compared to the lung. Luciferase
expression observed in these organs is probably originating
from a small fraction of the accumulated dose being able to
escape from uptake by the non-parenchymal macrophages
and to transfect parenchymal cells (e.g. hepatocytes) (56). We
hypothesize that the non-parenchymal macrophages have
been responsible for extensive suppression of transgene
expression in the transfected parenchymal cells, in the case
of transfection with CpGrich DNA complexes. Hepatosplenic
macrophages have found to be responsible for the capture of
a major part of the circulating DNA complexes (24). The
TLR9-mediated signaling of CpG motifs by macrophages has
shown to result in immune activation and high local levels of
pro-inflammatory cytokines (47). The beneficial effect of CpG
depletion is likely most obvious in those organs where immune
cells are easily accessible (liver and spleen) and therefore are
highly involved in the uptake and processing of the complexes,
compared to e.g. the lung where immune cells are muss less
accessible for interaction with circulating DNA complexes.
The exact mechanism by which CpG depletion improves
transgene expression still remains unclear. The superior in
vivo transgene expression profile of CpGfree DNA com-
plexes might have benefited from the lack of the de novo
plasmid methylation (15–17). The results from this study
demonstrates that removal of CpG motifs limits the immu-
nostimulatory effects of i.v. administered DNA liposome
formulations. A limited immune response may have contrib-
uted to the improved transgene expression by alleviating
plasmid promoter repression as well as toxicity towards
transfected cells and transgene products (26,29,30). The
extent to which both mechanisms contribute to the degree
and duration of transgene expression is likely dependent on
additional factors such as, amongst others, the acute toxicity
of the gene delivery system, as well as the type of organ(s)
and cell(s) being transfected.
CONCLUSION
This study is the first in demonstrating that the replace-
ment of CpGrich DNA by CpGfree DNA improves the
degree and duration of transgene expression after polymer-
mediated i.v. gene delivery. The effect is most pronounced in
the liver and spleen, and to a lesser extent in the tumor.
Therapeutic studies have to clarify whether CpG depletion
will enable further progression in tumor gene therapy.
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